Showing 3311-3320 of 5661 results for "".
- New Data Show Itch Reduction with Topical Roflumilast in Psoriasis and Seborrheic Dermatitishttps://practicaldermatology.com/news/new-data-show-itch-reduction-with-topical-roflumilast-in-psoriasis-and-seborrheic-dermatitis/2460937/New patient-reported outcomes data show once-daily, topical roflumilast provides significant reductions in itch. Once-daily roflumilast cream reduced both the severity and burden of itch, and improved quality of life in the DERMIS-1 and DERMIS-2 Phase 3 pivotal studies in chronic plaque psoriasis
- Lilly's Lebrikizumab Performs Well in Two Phase 3 AD Trialshttps://practicaldermatology.com/news/lillys-lebrikizumab-performs-well-in-two-phase-3-ad-trials/2460892/Eli Lilly and Company's lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), according to top-line results from ADvocate 1 and ADvocate 2. All primary and all key secondary en
- Dove, Conservation International Announce Million Dollar Forest Restoration Project to Fight Climate Changehttps://practicaldermatology.com/news/dove-conservation-international-announce-million-dollar-forest-restoration-project-to-fight-climate-change/2460822/Dove is launching the Dove Forest Restoration Project, one of the biggest protection and restoration efforts from any beauty brand to-date. The project is designed to protect and restore forests, protect the habitats of endangered species, and improve the livelihoods of 16,000 peo
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- Dominion Aesthetic Technologies Closes $23.7 Million Series B Financing to Accelerate the Commercialization of EONhttps://practicaldermatology.com/news/dominion-aesthetic-technologies-closes-237-million-series-b-financing-to-accelerate-the-commercialization-of-eon/2460672/Dominion Aesthetic Technologies, developers of EON, closed Series B financing, raising a total of $23.7 million. The series B funding will accelerate the manufacturing and commercialization of EON, an FDA-cleared 1064 nm robotic laser device used for touchless, external non-invasi
- Cerave Poll: Healthier Skin Tops New Year’s Resolutionshttps://practicaldermatology.com/news/cerave-poll-healthier-skin-tops-new-years-resolution-lists/2460652/The COVID-19 pandemic has taken its toll on every aspect of life including skin, according to a new survey from CeraVe. Fully 62 percent of Americans agree that they have experienced more skin troubles during the pandemic than ever before, with top concerns being dryness (51
- For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2https://practicaldermatology.com/news/for-upper-facial-lines-daxibotulinumtoxina-succeeds-in-phase-2/2460637/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- Positive Topline Data from Phase 2b Study of Roflumilast Foam for Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-data-from-phase-2b-study-of-roflumilast-foam-for-scalp-and-body-psoriasis/2460633/Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, shared positive top line data from a Phase 2b clinical trial evaluating ARQ-
- DermOQ To Buy Skin Products's ECHO2 Plus Oxygen Facial Treatment Product Linehttps://practicaldermatology.com/news/dermoq-to-buy-skin-products-incs-echo2-plus-oxygen-facial-treatment-product-line/2460569/DermOQ Inc. is purchasing Skin Products Inc.’s ECHO2 Plus and Oxyceuticals oxygen facial treatment product lines. DermOQ offers its topical oxygen products under the brand names DermOQ Oxygen Lab and